StreetInsider.com News Articles

Form 4 BIOADAPTIVES, INC. For: Aug 01 Filed by: FRISSORA MARK P

Tue, 04 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260804/26865971.html

Form 4 BIOADAPTIVES, INC. For: Aug 01 Filed by: FRISSORA MARK P

Tue, 04 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260804/26865971.html

Form 4 BIOADAPTIVES, INC. For: Aug 01 Filed by: FRISSORA MARK P

Tue, 04 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260804/26865971.html

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches

Thu, 23 Jul 2026 07:30:00 -0400

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.

“Ultimately, our mission

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness

Thu, 16 Jul 2026 08:30:00 -0400

LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body.

To address this, the Xcellara™ platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara™ base, validated by a human randomized controlled trial that documented an

BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells

Wed, 15 Jul 2026 08:30:00 -0400

LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial availability of XcellaraHeart™, a premium cardiovascular wellness formula that integrates two complementary areas of cellular health science: stem/progenitor cell mobilization and cardiovascular repair signaling support.

XcellaraHeart™ is built on the Company’s Xcellara™ base, which is supported by a randomized, double-blind, placebo-controlled human clinical trial documenting an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. The Company believes this clinical result provides a strong foundation

BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells

Wed, 15 Jul 2026 08:30:00 -0400

LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial availability of XcellaraHeart™, a premium cardiovascular wellness formula that integrates two complementary areas of cellular health science: stem/progenitor cell mobilization and cardiovascular repair signaling support.

XcellaraHeart™ is built on the Company’s Xcellara™ base, which is supported by a randomized, double-blind, placebo-controlled human clinical trial documenting an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. The Company believes this clinical result provides a strong foundation